JCI The Journal of Clinical Investigation

KBTBD13 is an actin-binding protein that modulates muscle kinetics

Josine M. de Winter, … , Nicol C. Voermans, Coen A.C. Ottenheijm

J Clin Invest. 2024;134(3):e179111. https://doi.org/10.1172/JCI179111.

Corrigendum

Original citation J Clin Invest. 2020;130(2):754–767. https://doi.org/10.1172/JCI124000. Citation for this corrigendum: J Clin Invest. 2024;134(3):e179111. https://doi.org/10.1172/JCI179111. In Table 1, the KBTBD13 mutation for Study ID Biopsy NEM6-F10 was incorrect. The correct table line from the table is below. The HTML and PDF files have been updated online. The authors regret the error.

Corrigendum

KBTBD13 is an actin-binding protein that modulates muscle kinetics

Josine M. de Winter, Joery P. Molenaar, Michaela Yuen, Robbert van der Pijl, Shengyi Shen, Stefan Conijn, Martijn van de Locht, Menne Willigenburg, Sylvia J.P. Bogaards, Esmee S.B. van Kleef, Saskia Lassche, Malin Persson, Dilson E. Rassier, Tamar E. Sztal, Avnika A. Ruparelia, Viola Oorschot, Georg Ramm, Thomas E. Hall, Zherui Xiong, Christopher N. Johnson, Frank Li, Balazs Kiss, Noelia Lozano-Vidal, Reinier A. Boon, Manuela Marabita, Leonardo Nogara, Bert Blaauw, Richard J. Rodenburg, Benno Küsters, Jonne Doorduin, Alan H. Beggs, Henk Granzier, Ken Campbell, Weikang Ma, Thomas Irving, Edoardo Malfatti, Norma B. Romero, Robert J. Bryson-Richardson, Baziel G.M. van Engelen, Nicol C. Voermans, and Coen A.C. Ottenheijm

Original citation *J Clin Invest*. 2020;130(2):754–767. https://doi.org/10.1172/JCI124000.

Citation for this corrigendum: *J Clin Invest*. 2024;134(3):e179111. https://doi.org/10.1172/JCI179111.

In Table 1, the *KBTBD13* mutation for Study ID Biopsy NEM6-F10 was incorrect. The correct table line from the table is below. The HTML and PDF files have been updated online.

The authors regret the error.

Table 1. Clinical characteristics and genetic information of patients and controls

Study ID TMS	Study ID biopsy	Sex	Onset	Age at biopsy	Age at TMS	Muscle weakness[A] at time of biopsy/ first consultation	Reported muscle slowness/stiffness	Result of biopsy	*KBTBD13* mutation
NEM6-T05	NEM6-F01	F	Childhood	42	49	Mild[B]	Stiffness	Cores and dystrophy	c.1222C>T (p.(Arg408Cys))
	NEM6-F02	F	Adulthood	43	NA	Mild	Stiffness	Cores and rods	c.1222C>T (p.(Arg408Cys))
NEM6-T03	NEM6-F03	F	Childhood	16	28	Mild	Slowness	Rods	No genetic confirmation Mother with c.1222C>T (p.(Arg408Cys)) mutation
	NEM6-F04	F	Adolescence	45	NA	Mild	Stiffness and slowness	Cores and rods	c.1222C>T (p.(Arg408Cys))
	NEM6-F05	M	Adulthood	62	NA	Mild	Stiffness	Normal	c.1222C>T (p.(Arg408Cys))
	NEM6-F06	F	Adolescence	34	NA	Moderate[C]	None	Rods	c.1222C>T (p.(Arg408Cys))
	NEM6-F07	F	Childhood	28	NA	No muscle weakness	Stiffness	Normal	c.247G>C (p.(Glu83Gln))
	NEM6-F08	M	Childhood	68	NA	Moderate	Slowness	Rods	c.1222C>T (p.(Arg408Cys))
	NEM6-F09	F	Unknown	45	NA	Unknown	Unknown	Cores and rods	c.1222C>T (p.(Arg408Cys))
	NEM6-F10	F	Childhood	56	NA	Mild	Slowness	Rods	c.1222C>T (p.(Arg408Ser))
NEM6-T07	NEM6-F11	F	Childhood	41	47	Mild	Stiffness and slowness	Cores, rods, and dystrophy	c.1170G>C (p.(Lys390Asn))
	NEM6-F12	M	Adulthood	54	NA	Mild[D]	Slowness	Normal	c.1107C>G (p.(Ile369Met))
NEM6-T01		M	Childhood	NA	52	Mild	Stiffness	NA	c.1222C>T (p.(Arg408Cys))
NEM6-T02		F	Childhood	32	33	Moderate	Stiffness	Cores and rods	c.1222C>T (p.(Arg408Cys))
NEM6-T06		M	Childhood	NA	45	Mild	Stiffness	NA	c.1222C>T (p.(Arg408Cys))
NEM6-T08		M	Childhood	NA	23	No muscle weakness	None	NA	c.1222C>T (p.(Arg408Cys))
NEM6-T09		M	Unknown	NA	49	Mild	None	NA	c.1222C>T (p.(Arg408Cys))
NEM6-T10		M	Childhood	30	36	Mild	Slowness	Cores and rods	c.1222C>T (p.(Arg408Cys))
NEM6-T11		F	Unknown	NA	21	Mild	Stiffness and slowness	NA	c.1222C>T (p.(Arg408Cys))
	CTRL-01	F	NA	65	NA	NA	NA	Normal	NA
	CTRL-02	M	NA	50	NA	NA	NA	Normal	NA
	CTRL-03	M	NA	44	NA	NA	NA	Normal	NA
	CTRL-04	M	NA	50	NA	NA	NA	Normal	NA
	CTRL-05	F	NA	52	NA	NA	NA	Normal	NA
	CTRL-06	F	NA	51	NA	NA	NA	Normal	NA

All the biopsies that showed cores and/or rods also showed myopathic changes, including an increase of internal nuclei, fiber type disproportion, and fiber type I predominance. NA, not assessed. [A]Muscle weakness: proximal muscle groups are more affected than distal ones. Axial weakness is also present. No facial weakness. [B]Mild: strength is at least MRC scale 4. [C]Moderate: strength is MRC scale 3–4. [D]This patient has predominantly distal weakness and thus differs from the other patients.